


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Lake Huron Medical Center</p> <p>2. 2601 Electric Avenue Port Huron, MI 48060-6815</p>	<p>In accordance with letter dated November 21, 2017.</p> <p>3. License number: 21-15638-01 is amended in its entirety to read as follows:</p>	<p>4. Expiration Date: May 31, 2025</p> <p>5. Docket No.: 030-09491 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Iodine-125 permitted by 10 CFR 35.400</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources (Bard Brachytherapy, Inc., Model STM 1251; IsoAid L.L.C., Model IAI-125A; Medi-Physics, Inc., Model 6711 and 6733; North American Scientific, Inc., Model MED 3631; Theragenics Corporation, Model AgX100)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 1 curie total</p> <p>D. 500 millicuries total</p> <p>9. Authorized use</p> <p>A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.</p> <p>B. Any imaging and localization study permitted by 10 CFR 35.200.</p> <p>C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.</p> <p>D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.</p>



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
21-15638-01

Docket or Reference Number
030-09491

Amendment No. 39

- | | | | |
|---|--|--|---|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use |
| E. Iridium-192 permitted by 10 CFR 35.400 | E. Sealed Sources (Best Medical International, Inc., Model 2300 Series and 81-01 Series) | E. 500 millicuries total | E. Any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| F. Cesium-131 permitted by 10 CFR 35.400 | F. Sealed Sources (IsoRay, Model CS-1) | F. 500 millicuries total | F. Any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| G. Cesium-137 permitted by 10 CFR 35.400 | G. Sealed Sources (3M, Model 6500 Series; AEA Technology, Model CDC T1; Eckert & Ziegler Istoproducts dba Isotope Products Laboratories, Model 67-6500 Series) | G. 1 curie total | G. Any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| H. Palladium-103 permitted by 10 CFR 35.400 | H. Sealed Sources (Best Medical International, Inc., Model 2300 Series; North American Scientific, Inc., Model MED 3631; Theragenics Corporation, Model TheraSeed 200) | H. 500 millicuries total | H. Any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| I. Any byproduct material permitted by 10 CFR 31.11 | I. Prepackaged Kits | I. 5 millicuries total | I. In vitro studies. |

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at: 2601 Electric Avenue, Port Huron, Michigan, 48060
11. The Radiation Safety Officer (RSO) for this license is Jeffery N. Adams, M.S., DABR.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
21-15638-01

Docket or Reference Number
030-09491

Amendment No. 39

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User(M.D.,D.O.,etc.)

Material and Use

Fredrick Coop, M.D.

10 CFR 35.100, 35.200, 35.300 (limited to oral administration of sodium iodide I-131 for diagnostic studies) and 31.11

Jose A. Carrion, M.D.

10 CFR 35.100, 35.200, 35.300 (limited to oral administration of sodium iodide I-131 for diagnostic studies) and 31.11

Sushma Reddy, M.D.

10 CFR 35.300 (limited to oral administration of sodium iodide I-131)

Kanu Bhaidas Dalal, M.D.

10 CFR 35.300 and 35.400

Herminio Calderon, M.D.

10 CFR 35.100, 35.200, 35.300 and 31.11

Edward Mauch, M.D.

10 CFR 35.100, 35.200 and 35.300 (limited to oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Leopold Fregoli, M.D.

10 CFR 35.100, 35.200 and 35.300 (limited to oral administration of sodium iodide I-131 for diagnostic studies)

David Peterson Tracy, M.D.

10 CFR 35.100, 35.200 and 35.300 (limited to oral administration of sodium iodide I-131 for diagnostic studies)

Daniel Kirk Shogren, M.D.

10 CFR 35.100, 35.200 and 35.300 (limited to oral administration of sodium iodide I-131 for diagnostic studies)


John Ference, M.D.

10 CFR 35.100, 35.200 and 35.300 (limited to oral administration of sodium iodide I-131 for diagnostic studies)


**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
21-15638-01Docket or Reference Number
030-09491

Amendment No. 39

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated September 4, 2014 (with attachments) (ML14248A686)
 - B. Application dated March 6, 2015 (received March 6, 2015, with attachments) (ML15142A832)
 - C. Application dated March 6, 2015 (received May 13, 2015, with attachments) (ML15142A833)
 - D. Letter dated June 22, 2015 (ML15180A341)
 - E. Letter dated September 8, 2015 (ML15252A299)
 - F. Letter dated September 30, 2015 (ML15278A369)
 - G. Letter dated July 11, 2016 (ML16207A514)
 - H. Letter dated November 21, 2017 (ML17333A359)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: January 31, 2018By: 
Jennifer L. Bishop
Region 3